Multiple Sclerosis, Spasticity
Conditions
Keywords
Spasticity, Multiple Sclerosis
Brief summary
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to Sativex.
Detailed description
This 19 week, multicentre study was conducted in two phases. Phase A was a preliminary, single-blind four week treatment period to identify subjects with a capacity to respond to Sativex; eligible, consenting subjects entered a seven day screening period prior to returning to the study centre to begin a four week single-blind course of Sativex treatment. At the end of this phase, subjects' response to Sativex was assessed; those with the capacity to respond (i.e. at least a 20% reduction in mean 0-10 point numerical rating scale (NRS) spasticity score between screening and the end of the four week Phase A treatment) were eligible for entry into Phase B while those who did not respond took no further part in the study other than a follow up visit 14 days later. Phase B was a 12 week double-blind, randomised, placebo controlled, parallel group study with visits at 28 day intervals and a final follow up visit 14 days after completion or withdrawal. The level of spasticity, spasm frequency and sleep disruption were collected each day during the entire study via an interactive voice response system (IVRS). In addition, study medication dosing data were recorded via IVRS throughout Phases A and B. Assessments of other secondary and functional measures of spasticity, safety and tolerability, QOL (quality of life) and mood were also gathered throughout the study.
Interventions
DRUGSativex®
containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
DRUGPlacebo
containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Sponsors
Jazz Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to give written informed consent for participation in the study. * Male or female, aged 18 years or above. * Subject is able (in the investigator's opinion) and willing to comply with all study requirements. * Diagnosed with any disease sub-type of MS of at least six months duration. * Spasticity due to MS of at least three months duration, which is not wholly relieved with current anti-spasticity therapy, and which is expected to remain stable for the duration of the study. * Subject fulfils at least one of the two criteria below. Subject must be either: Currently established on a regular dose of anti-spasticity therapy or Previously tried and failed, or could not tolerate suitable anti-spasticity therapy. * Subject is currently receiving a stable regimen (for at least 30 days prior to study entry) of all medications that may have an effect on spasticity; and willing to maintain this for the duration of the study. If the subject is currently taking disease-modifying medication, this must be at a stable dose for at least three months prior to the screening visit; the dose must also remain stable for the duration of the study. * Willing for his or her name to be notified to his or her primary care physician, and consultant and the responsible authorities for participation in this study, as applicable.
Exclusion criteria
* Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity. * Subject's medical history suggests that relapse/remission is likely to occur during the study (over the next 19 weeks) which, in the opinion of the investigator, is expected to influence the subject's spasticity. * Currently receiving a prohibited medication and unwilling to stop for the stated period prior to the screening visit and for the duration of the study. * Any known or suspected history of: schizophrenia or other psychotic illness;diagnosed dependence disorder;poorly controlled epilepsy or recurrent seizures;hypersensitivity to cannabinoids. * Significant cardiac, renal or hepatic disease. * Female subjects of child bearing potential and male subjects whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter. * Female subject who is pregnant, lactating or planning pregnancy during the course of the study or for three months thereafter. * Subjects who have received an IMP within the 12 weeks before Visit 1. * Any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study. * Following a physical examination, the subject has any abnormalities that, in the opinion of the investigator, would prevent them from safely participating in the study. * Unwilling to abstain from donation of blood during the study. * Travel outside the country of residence planned during the study. * Subjects previously randomised into this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). | Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17) | Subjects were asked On a scale of '0 to 10' please indicate the average level of your spasticity over the last 24 hours with the anchors: 0 = 'no spasticity' and 10 = 'worst possible spasticity'. They were asked to relate 'no spasticity' to the time prior to the onset of their spasticity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline. | Baseline (Day 1) - End of treatment (last 7 days of Week 17) | A subject was classified as a responder in the evaluable period provided they did not withdraw due to lack of efficacy and achieved at least a 30% or 50% reduction (i.e. improvement) in the mean NRS spasticity score from baseline (Day 1) to the end of treatment(last 7 days of Week 17 Phase B). All other subjects and subjects without evaluable data were considered non-responders. |
| Change in Spasm Frequency (Number of Spasms Per Day) From Baseline to End of Treatment (Phase B). | Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17) | The subjects' baseline spasm frequency was the mean of the last seven days scores (Week 4) of Phase A treatment. The variable for analysis was the change in mean spasm frequency from baseline to the end of treatment (last 7 days of Week 17 Phase B). |
| Change in Sleep Disruption (Daily 11-point NRS) From Baseline to End of Treatment (Phase B). | Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17) | The sleep disruption NRS score was recorded by subjects via a daily call to the interactive voice response system at bedtime. Subjects were asked On a scale of '0 to 10' please indicate how you your spasticity disrupted your sleep last night with the anchors: 0 = 'did not disrupt sleep' and 10 = 'completely disrupted (unable to sleep at all)'. |
| Change in Spasticity as Measured Using the Modified Ashworth Scale From Baseline to End of Treatment (Phase B). | Baseline (End of Week 4) - End of treatment (End of Week 17) | All 20 muscle groups were assessed for spasticity (using a 1-5 scale): 1= no increase in muscle tone to 5= passive movement is difficult and affected part is rigid in flexion or extension. The score for all 20 muscle groups were added to give a total score out of 100; minimum score was 20. A decrease in score indicates an improvement in condition. |
| Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs. | Baseline (End of Week 4) - End of treatment (End of Week 17) | Arm - 3 movements were pinch grip, elbow flexion and shoulder abduction. Leg - 3 movements were ankle dorsiflexion, knee extension and hip flexion. The total arm and leg score was the addition of the score for the 3 arm movements and 3 leg movements, respectively. One point was then added to each limb score to give a maximum score of 100; minimum was 1 point. Where both arms (or both legs) were assessed, the average of the two limbs scores was used as the assessment score; otherwise the affected limb total score was used. An increase in score indicates an improvement in condition. |
| Change in Timed 10-metre Walk From Baseline to End of Treatment (Phase B). | Baseline (End of Week 4) - End of treatment (End of Week 17) | Only those subjects for whom it was appropriate (i.e. ambulatory subjects) were timed how long it took to walk 10 metres. Walk time was only assessed for subjects who successfully completed the Timed 10 Metre Walk. A negative difference from baseline indicates an improvement walk time. |
| Subject Global Impressions of Change at End of Treatment (Phase B). | End of Treatment (WeeK 17) | — |
| Carer Global Impressions of Change at of Treatment (Phase B). | End of treatment (Week 17) | — |
| Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | End of treatment (week 17) | — |
| Physician Global Impressions of Change at End of Treatment (Phase B). | End of treatment (week 17) | — |
| Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B) | [Baseline (End of Week 4) - End of treatment (End of Week 17) | The EQ-5D questionnaire provided two outcomes: 1. A weighted health state index visual analogue scale (VAS) 2. A self-rated health status VAS EQ-5D Health Status VAS Scale: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score indicates an improvement in condition. The weighted health state index used the same VAS as above but was calculated for each assessment without imputation to account for missing values i.e., if one or more individual items was missing then the whole index was missing. |
| Mood Assessment: Change in Beck Depression Inventory - II (BDI-II)From Baseline to End of Treatment (Phase B) | Baseline (End of week 4) - end of treatment (end of week 17) | This was a 21-question multiple choice self-report inventory. Subjects' responses to the 21 questions were assigned a score ranging from zero to three, indicating the severity of the symptom. The sum of all BDI-II question scores indicated the severity of depression; score range 0-63. An decrease in score indicates an improvement in condition. |
Countries
United Kingdom
Participant flow
Pre-assignment details
Only those subjects who were deemed responders to Sativex from Phase A (i.e. at least a 20% reduction in mean 0-10 point numerical rating scale (NRS) spasticity score between screening and the end of the four week Phase A treatment) were eligible to enter Phase B of the study.
Participants by arm
| Arm | Count |
|---|---|
| Sativex (Phase B) contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours. | 124 |
| Placebo (Phase B) Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours. | 117 |
| Total | 241 |
Baseline characteristics
| Characteristic | Sativex (Phase B) | Placebo (Phase B) | Total |
|---|---|---|---|
| Age, Continuous | 49.1 Years STANDARD_DEVIATION 9.09 | 48.1 Years STANDARD_DEVIATION 9.59 | 48.6 Years STANDARD_DEVIATION 9.33 |
| Baseline Spasticity numerical rating scale (NRS) Score Phase B | 3.87 Score STANDARD_DEVIATION 1.49 | 3.92 Score STANDARD_DEVIATION 1.55 | 3.90 Score STANDARD_DEVIATION 1.51 |
| Duration of Multiple Sclerosis Phase B | 13.3 years STANDARD_DEVIATION 8.29 | 11.8 years STANDARD_DEVIATION 7.38 | 12.6 years STANDARD_DEVIATION 7.88 |
| Duration of Spasticity Phase B | 8.6 years STANDARD_DEVIATION 6.89 | 6.7 years STANDARD_DEVIATION 5.4 | 7.7 years STANDARD_DEVIATION 6.27 |
| Expanded Disability Status Scale (EDSS)- Phase B | 6.5 Score STANDARD_DEVIATION 1.46 | 6.0 Score STANDARD_DEVIATION 1.44 | 6.0 Score STANDARD_DEVIATION 1.45 |
| Sex: Female, Male Female | 72 Participants | 73 Participants | 145 Participants |
| Sex: Female, Male Male | 52 Participants | 44 Participants | 96 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 66 / 124 | 40 / 117 |
| serious Total, serious adverse events | 6 / 124 | 1 / 117 |
Outcome results
Primary
The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B).
Subjects were asked On a scale of '0 to 10' please indicate the average level of your spasticity over the last 24 hours with the anchors: 0 = 'no spasticity' and 10 = 'worst possible spasticity'. They were asked to relate 'no spasticity' to the time prior to the onset of their spasticity.
Time frame: Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). | 3.68 Points on scale | Standard Deviation 1.83 |
| Placebo (Phase B) | The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). | 4.56 Points on scale | Standard Deviation 2.31 |
p-value: 0.000295% CI: [-1.29, -0.4]ANCOVA
Secondary
Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B).
Time frame: End of treatment (week 17)
Population: Sample sizes were reduced as not all subjects had a Carer to make this assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 27 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 6 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Much better | 9 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Much worse | 4 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | No change | 24 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 0 participants |
| Sativex (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Very much better | 1 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 2 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Very much better | 1 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Much better | 8 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 14 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | No change | 30 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 11 participants |
| Placebo (Phase B) | Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B). | Much worse | 3 participants |
p-value: 0.061395% CI: [0.973, 3.301]Regression, Logistic
Secondary
Carer Global Impressions of Change at of Treatment (Phase B).
Time frame: End of treatment (Week 17)
Population: Sample sizes were reduced as not all subjects had a Carer to make this assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Minimally better | 31 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Minimally worse | 4 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Much better | 15 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Much worse | 2 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | No change | 16 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Very much worse | 1 participants |
| Sativex (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Very much better | 2 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Very much worse | 2 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Very much better | 0 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Much better | 11 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Minimally better | 19 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | No change | 24 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Minimally worse | 8 participants |
| Placebo (Phase B) | Carer Global Impressions of Change at of Treatment (Phase B). | Much worse | 5 participants |
p-value: 0.005395% CI: [1.297, 4.443]Regression, Logistic
Secondary
Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B)
The EQ-5D questionnaire provided two outcomes: 1. A weighted health state index visual analogue scale (VAS) 2. A self-rated health status VAS EQ-5D Health Status VAS Scale: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score indicates an improvement in condition. The weighted health state index used the same VAS as above but was calculated for each assessment without imputation to account for missing values i.e., if one or more individual items was missing then the whole index was missing.
Time frame: [Baseline (End of Week 4) - End of treatment (End of Week 17)
Population: EQ-5D Health State Index Sativex n=117 and placebo n=111. EQ-5D Health Status VAS Sativex n=121 and placebo n=117.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Sativex (Phase B) | Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B) | EQ-5D Health State Index | 0.003 score on scale | Standard Deviation 0.155 |
| Sativex (Phase B) | Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B) | EQ-5D Health Status VAS | -0.7 score on scale | Standard Deviation 15.3 |
| Placebo (Phase B) | Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B) | EQ-5D Health State Index | -0.013 score on scale | Standard Deviation 0.176 |
| Placebo (Phase B) | Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B) | EQ-5D Health Status VAS | -2.8 score on scale | Standard Deviation 19.9 |
Comparison: For Health State Indexp-value: 0.283695% CI: [-0.02, 0.07]ANCOVA
Comparison: Health Status VASp-value: 0.564495% CI: [-3.01, 5.5]ANCOVA
Secondary
Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs.
Arm - 3 movements were pinch grip, elbow flexion and shoulder abduction. Leg - 3 movements were ankle dorsiflexion, knee extension and hip flexion. The total arm and leg score was the addition of the score for the 3 arm movements and 3 leg movements, respectively. One point was then added to each limb score to give a maximum score of 100; minimum was 1 point. Where both arms (or both legs) were assessed, the average of the two limbs scores was used as the assessment score; otherwise the affected limb total score was used. An increase in score indicates an improvement in condition.
Time frame: Baseline (End of Week 4) - End of treatment (End of Week 17)
Population: For Arm subject numbers were 23 for Sativex and 22 for placebo. For Leg subject numbers were 91 for Sativex and 92 for placebo.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Sativex (Phase B) | Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs. | Arm | 0.5 Score on scale | Standard Deviation 15.62 |
| Sativex (Phase B) | Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs. | Leg | -1.3 Score on scale | Standard Deviation 7.64 |
| Placebo (Phase B) | Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs. | Arm | 0.8 Score on scale | Standard Deviation 10.6 |
| Placebo (Phase B) | Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs. | Leg | -1.0 Score on scale | Standard Deviation 9.48 |
Comparison: For Armp-value: 0.5695% CI: [-12.75, 7.04]ANCOVA
Comparison: For legp-value: 0.9895% CI: [-2.56, 2.64]ANCOVA
Secondary
Change in Sleep Disruption (Daily 11-point NRS) From Baseline to End of Treatment (Phase B).
The sleep disruption NRS score was recorded by subjects via a daily call to the interactive voice response system at bedtime. Subjects were asked On a scale of '0 to 10' please indicate how you your spasticity disrupted your sleep last night with the anchors: 0 = 'did not disrupt sleep' and 10 = 'completely disrupted (unable to sleep at all)'.
Time frame: Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | Change in Sleep Disruption (Daily 11-point NRS) From Baseline to End of Treatment (Phase B). | 1.71 Points on scale | Standard Deviation 1.65 |
| Placebo (Phase B) | Change in Sleep Disruption (Daily 11-point NRS) From Baseline to End of Treatment (Phase B). | 2.65 Points on scale | Standard Deviation 2.45 |
p-value: <0.000195% CI: [-1.25, -0.51]ANCOVA
Secondary
Change in Spasm Frequency (Number of Spasms Per Day) From Baseline to End of Treatment (Phase B).
The subjects' baseline spasm frequency was the mean of the last seven days scores (Week 4) of Phase A treatment. The variable for analysis was the change in mean spasm frequency from baseline to the end of treatment (last 7 days of Week 17 Phase B).
Time frame: Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | Change in Spasm Frequency (Number of Spasms Per Day) From Baseline to End of Treatment (Phase B). | 5.56 Spasms per day | Standard Deviation 10.33 |
| Placebo (Phase B) | Change in Spasm Frequency (Number of Spasms Per Day) From Baseline to End of Treatment (Phase B). | 7.70 Spasms per day | Standard Deviation 12.02 |
p-value: 0.004695% CI: [-4.27, -0.79]ANCOVA
Secondary
Change in Spasticity as Measured Using the Modified Ashworth Scale From Baseline to End of Treatment (Phase B).
All 20 muscle groups were assessed for spasticity (using a 1-5 scale): 1= no increase in muscle tone to 5= passive movement is difficult and affected part is rigid in flexion or extension. The score for all 20 muscle groups were added to give a total score out of 100; minimum score was 20. A decrease in score indicates an improvement in condition.
Time frame: Baseline (End of Week 4) - End of treatment (End of Week 17)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | Change in Spasticity as Measured Using the Modified Ashworth Scale From Baseline to End of Treatment (Phase B). | -0.1 Score on scale | Standard Deviation 8.25 |
| Placebo (Phase B) | Change in Spasticity as Measured Using the Modified Ashworth Scale From Baseline to End of Treatment (Phase B). | 1.8 Score on scale | Standard Deviation 7.79 |
p-value: 0.093995% CI: [-3.8, 0.3]ANCOVA
Secondary
Change in Timed 10-metre Walk From Baseline to End of Treatment (Phase B).
Only those subjects for whom it was appropriate (i.e. ambulatory subjects) were timed how long it took to walk 10 metres. Walk time was only assessed for subjects who successfully completed the Timed 10 Metre Walk. A negative difference from baseline indicates an improvement walk time.
Time frame: Baseline (End of Week 4) - End of treatment (End of Week 17)
Population: Only those subjects for whom it was appropriate (i.e. ambulatory subjects) were timed how long it took to walk 10 metres. Walk time was only assessed for subjects who successfully completed the Timed 10 Metre Walk.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | Change in Timed 10-metre Walk From Baseline to End of Treatment (Phase B). | -2.3 Seconds | Standard Deviation 8.38 |
| Placebo (Phase B) | Change in Timed 10-metre Walk From Baseline to End of Treatment (Phase B). | 2.0 Seconds | Standard Deviation 15.16 |
p-value: 0.068795% CI: [-6.95, 0.26]ANCOVA
Secondary
Mood Assessment: Change in Beck Depression Inventory - II (BDI-II)From Baseline to End of Treatment (Phase B)
This was a 21-question multiple choice self-report inventory. Subjects' responses to the 21 questions were assigned a score ranging from zero to three, indicating the severity of the symptom. The sum of all BDI-II question scores indicated the severity of depression; score range 0-63. An decrease in score indicates an improvement in condition.
Time frame: Baseline (End of week 4) - end of treatment (end of week 17)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sativex (Phase B) | Mood Assessment: Change in Beck Depression Inventory - II (BDI-II)From Baseline to End of Treatment (Phase B) | 0.5 Score on scale | Standard Deviation 5.01 |
| Placebo (Phase B) | Mood Assessment: Change in Beck Depression Inventory - II (BDI-II)From Baseline to End of Treatment (Phase B) | 0.4 Score on scale | Standard Deviation 6.54 |
p-value: 0.936995% CI: [-1.62, 1.49]ANCOVA
Secondary
Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline.
A subject was classified as a responder in the evaluable period provided they did not withdraw due to lack of efficacy and achieved at least a 30% or 50% reduction (i.e. improvement) in the mean NRS spasticity score from baseline (Day 1) to the end of treatment(last 7 days of Week 17 Phase B). All other subjects and subjects without evaluable data were considered non-responders.
Time frame: Baseline (Day 1) - End of treatment (last 7 days of Week 17)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sativex (Phase B) | Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline. | 30% improvement in spasticity | 92 participants |
| Sativex (Phase B) | Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline. | 50% improvement in spasticity | 56 participants |
| Placebo (Phase B) | Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline. | 30% improvement in spasticity | 60 participants |
| Placebo (Phase B) | Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline. | 50% improvement in spasticity | 39 participants |
Comparison: 30% respondersp-value: 0.000395% CI: [1.589, 4.694]Regression, Logistic
Comparison: 50% Respondersp-value: 0.061295% CI: [0.977, 2.777]Regression, Logistic
Secondary
Physician Global Impressions of Change at End of Treatment (Phase B).
Time frame: End of treatment (week 17)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 0 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 45 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Very much better | 6 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Much better | 44 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | No change | 17 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 4 participants |
| Sativex (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Much worse | 6 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 0 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | No change | 37 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Much worse | 4 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Very much better | 8 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 13 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Much better | 29 participants |
| Placebo (Phase B) | Physician Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 26 participants |
p-value: 0.004595% CI: [1.232, 3.112]Regression, Logistic
Secondary
Subject Global Impressions of Change at End of Treatment (Phase B).
Time frame: End of Treatment (WeeK 17)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 39 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 4 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Much better | 40 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Much worse | 6 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | No change | 17 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 1 participants |
| Sativex (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Very much better | 14 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Very much worse | 3 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Very much better | 10 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Much better | 28 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Minimally better | 33 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | No change | 35 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Minimally worse | 7 participants |
| Placebo (Phase B) | Subject Global Impressions of Change at End of Treatment (Phase B). | Much worse | 1 participants |
p-value: 0.023495% CI: [1.075, 2.698]Regression, Logistic